Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Riese

Showing results (771-780 of 804) with videos related to

Pageof 81
Sort By:
Nature Metabolism|July 23, 2021
Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a studyMarja K Puurunen, Jerry Vockley, Shawn L Searle, et al.
Prehospital and Disaster Medicine|October 22, 2008
Media coverage of violent deaths in iraQ: an opportunistic capture-recapture assessmentAnne Siegler, Leslie Roberts, Erin Balch, et al.
Pathogens (Basel, Switzerland)|January 8, 2025
Vaccination Schedule and Age Influence Impaired Responsiveness to Hepatitis B Vaccination: A Randomized Trial in Central AsiaJanyn Heisig, Zuridin Sh Nurmatov, Peggy Riese, et al.
Frontiers in Immunology|November 2, 2023
CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumorsAnna Christina Dragon, Luca Marie Beermann, Melina Umland, et al.
Pharmacological Reviews|January 6, 2022
The Yin and Yang of ERBB4: Tumor Suppressor and OncoproteinLauren M Lucas, Vipasha Dwivedi, Jared I Senfeld, et al.
The Journal of Experimental Medicine|May 27, 2009
CD1c bypasses lysosomes to present a lipopeptide antigen with 12 amino acidsIldiko Van Rhijn, David C Young, Annemieke De Jong, et al.
Molecular Therapy. Methods & Clinical Development|June 9, 2015
Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMVAnusara Daenthanasanmak, Gustavo Salguero, Bala Sai Sundarasetty, et al.
The Oncologist|March 19, 2017
Academic Cancer Center Phase I Program DevelopmentArthur E Frankel, Keith T Flaherty, George J Weiner, et al.
Oncoimmunology|October 6, 2018
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanomaDavid L Bajor, Rosemarie Mick, Matthew J Riese, et al.
Cancers|November 9, 2024
High Expression of the Tumor Suppressor Protein ITIH5 in Cholangiocarcinomas Correlates with a Favorable PrognosisVerena J Dreyer, Jia-Xin Shi, Michael Rose, et al.
Pageof 81

Showing results (771-780 of 804) with videos related to

Sort By:
Pageof 81
Nature Metabolism|July 23, 2021
Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a studyMarja K Puurunen, Jerry Vockley, Shawn L Searle, et al.
Prehospital and Disaster Medicine|October 22, 2008
Media coverage of violent deaths in iraQ: an opportunistic capture-recapture assessmentAnne Siegler, Leslie Roberts, Erin Balch, et al.
Pathogens (Basel, Switzerland)|January 8, 2025
Vaccination Schedule and Age Influence Impaired Responsiveness to Hepatitis B Vaccination: A Randomized Trial in Central AsiaJanyn Heisig, Zuridin Sh Nurmatov, Peggy Riese, et al.
Frontiers in Immunology|November 2, 2023
CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumorsAnna Christina Dragon, Luca Marie Beermann, Melina Umland, et al.
Pharmacological Reviews|January 6, 2022
The Yin and Yang of ERBB4: Tumor Suppressor and OncoproteinLauren M Lucas, Vipasha Dwivedi, Jared I Senfeld, et al.
The Journal of Experimental Medicine|May 27, 2009
CD1c bypasses lysosomes to present a lipopeptide antigen with 12 amino acidsIldiko Van Rhijn, David C Young, Annemieke De Jong, et al.
Molecular Therapy. Methods & Clinical Development|June 9, 2015
Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMVAnusara Daenthanasanmak, Gustavo Salguero, Bala Sai Sundarasetty, et al.
The Oncologist|March 19, 2017
Academic Cancer Center Phase I Program DevelopmentArthur E Frankel, Keith T Flaherty, George J Weiner, et al.
Oncoimmunology|October 6, 2018
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanomaDavid L Bajor, Rosemarie Mick, Matthew J Riese, et al.
Cancers|November 9, 2024
High Expression of the Tumor Suppressor Protein ITIH5 in Cholangiocarcinomas Correlates with a Favorable PrognosisVerena J Dreyer, Jia-Xin Shi, Michael Rose, et al.
Pageof 81